Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
b. Nivolumab monotherapy
c. Nivolumab and Ipilimumab
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q3. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.
Q4. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.
